TARX Tarsier Pharma Ltd.

Executive Summary

Tarsier Pharma, an Israeli late clinical-stage biopharmaceutical company focused on inflammatory ocular diseases, files Amendment No. 2 to its F-1 registration statement for an IPO of 5,000,000 ordinary shares at an estimated price range of $8.00 to $10.00 per share (midpoint $9.00). Net proceeds of approximately $41.0 million will primarily fund the Phase 3 pivotal trial of lead candidate TRS01 for non-infectious anterior uveitis and uveitic glaucoma, NDA preparation, and TRS02 development. The company has a history of losses ($5.07 million in 2025), a going concern risk, and its prior Phase 3 trial missed the primary endpoint, though an FDA SPA agreement supports a new trial design with IOP as the primary endpoint.

Key Financial Metrics

Actionable Insight

Key Facts

• Offering 5,000,000 ordinary shares at $8.00–$10.00 per share; estimated net proceeds of $41.0 million
• Net loss of $5.07 million for 2025; accumulated deficit of $26.93 million as of Dec 31, 2025
• Going concern risk; existing cash insufficient to fund operations for next 12 months
• Prior Phase 3 TRS4Vision trial missed primary endpoint (ACC=0), but post-hoc IOP data supported SPA agreement with FDA for new pivotal trial (Tarsier-04) with IOP safety as primary endpoint
• Proceeds to fund Tarsier-04 trial, NDA prep ($6M), TRS02 R&D ($4M), and $0.678M CEO loan/deferred comp repayment

Financial Impact

Raises approximately $41.0 million in net proceeds; will require substantial additional funding beyond this offering to complete commercialization

Risk Factors

• Clinical trial failure: prior Phase 3 missed endpoint; new endpoint is safety-based and novel
• Going concern: existing cash + IPO proceeds estimated to fund only ~24 months; significant additional capital needed
• Regulatory: SPA agreement does not guarantee approval; FDA may require more data
• Dilution: substantial dilution to existing shareholders; new investors face 83.6% dilution per share

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

US Market Status

Related Tickers